CAT | market-pulse
Market Pulse Report
MP`s Market Commentary
Is the correction over From a technical perspective it looks like the market`s correction is complete and bullish forces are taking over. To help ease the European debt crisis the central banks acted globally. The Major Central Banks added liquidity to the world`s financial sytem. These actions should tip the scales into the bulls favor. The Dow looks like it double bottomed. The connecting bottoms are 10,400 area on October 4th and again on November 25th at 11,232.56. I am looking for a strong upward push into the year end. The 3rd quarter earnings reports have been very good and some of our economic data at home is also getting better. For small cap companies this is probably a great time to tell your story. If you are interested in our services call us at 1-800-290-8935 for your special rate to try us out. On Wednesday, stocks surged after major central banks agreed to make cheaper dollar loans for struggling European banks to prevent the euro-zone debt woes from turning into a full-blown credit crisis. The Dow scored its largest daily points gain since March 23, 2009. Copper and oil futures rose sharply. Other economically sensitive sectors, including energy, materials and industrials, also were strong performers for the day. The latest U.S. data suggested the U.S. economy was moving more solidly toward recovery. The Dow Jones industrial average shot up 490.05 points, or 4.24 percent, to end at 12,045.68. The Standard & Poor`s 500 Index jumped 51.77 points, or 4.33 percent, to 1,246.96. The Nasdaq Composite Index soared 104.83 points, or 4.17 percent, to close at 2,620.34. View more market information at market-pulse.com
MP`s Hot Stock Picks
Stock Pick Meanings
These stock picks are the investment opinions of MP`s editor and reflect MP`s belief regarding the potential price movement over the next one to four weeks of trading of each of the stocks presented. This analysis is done from a technical and fundamental perspective. MP rates them as follows:
Cisco Systems, Inc. (Nasdaq: CSCO) : Market Outperform.
Apple Inc. (Nasdaq: AAPL) : Market Outperform.
Deere & Company (NYSE: DE) : Market Outperform.
In this issue · MP`s Market Commentary · MP`s Hot Stock Picks · Cisco Systems, Inc. (Nasdaq: CSCO) : – Market Outperform . · Apple Inc. (Nasdaq: AAPL) : – Market Outperform. · Deere & Company (NYSE: DE) : – Market Outperform.
Wouldn`t your company love to be the premium quality stock pick sent directly to our subscriber`s inbox — At a bargain basement blow out rate to you! If you have positive news upcoming, or already have an existing IR service, Market Pulse can supplement that service and get you enhanced exposure. The bottom line is more investors could become aware of your company and its positive news.
Are your press releases being seen by the financial community Coverage of your company`s positive press releases is one of our specialties .
Traditional thinking by a company is that your news will be seen if you cover your own company. This is not always effective as a following is needed in the financial media, which is what Market Pulse`s specialty has been over the past 15 years. The Investment Opinion Press Release consists of your company`s name, ticker symbol/exchange and current news release that is attached to other stock ticker symbols that are in the news and acting well as of late. Some of these companies have a much larger shareholder base and this helps your company receive additional exposure. Call us at 800.290.8935 for your low rate to try the service! Please visit our website atwww.market-pulse.com .
If you are interested in a proposal for an awareness campaign, please contact Market Pulse LLC at 800-290-8935 or via email at ceo@market-pulse.com .
Market Pulse All Rights Reserved.
©2011 Market Pulse
American Jianye Greentech Holdings, Ltd. (OTCBB: AJGH) Press Release
Dear subscriber,
Welcome to Market Pulse`s online newsletter. Market Pulse is a small-cap investor`s first stop Web page. Each month, our user-friendly Web site profiles new and emerging companies that have excellent potential. We also feature stock picks , quotes, charts, news headlines and other valuable information that is easily accessed. We recommend that anyone investing perform his or her own due diligence.
Market Pulse has issued its current profile for American Jianye Greentech Holdings, Ltd. (OTCBB: AJGH) to the investment community! Stay Tuned For Frequent Updates at www.market-pulse.com .
Featured Company
American Jianye Greentech Holdings, Ltd. (OTCBB: AJGH) is a rapidly growing developer, manufacturer and distributor of alcohol-based and renewable clean fuel products in China. The company`s alcohol-based fuels are comparable to unleaded gasoline with octane ratings ranging from #90 to #108, but burn with higher efficiency and significantly lower toxic waste emissions than unleaded gasoline. The unique combination of catalysts in the fuel enhance fuel octane rating and engine power, inhibit the premature oxidation of the fuel, help remove sediment in the carburetor, and prevent the erosion of the engine cylinder surface. American Jianye has over $15M invested in R&D to date. AJGH has 7 domestic and 2 international patents protecting their unique technology creating many proprietary advantages over competing alcohol-based fuels. Due to their unique technology and process, no engine modifications are required to use their fuels. Similarly, there is no need for gas station modification. AJGH`s process allows for the production of Methanol automobile fuel under normal atmospheric conditions and temperatures, as well as at temperatures as low as -30°C (-22°F). Also, AJGH`s production process produces no significant hazardous waste or pollution. Demand is far outstripping supply for alcohol-based and renewable clean fuel. Chinese consumers were forecasted to buy a record 15 million vehicles in 2010, shattering the record 13.5 million in 2009 that made the country the world`s top car buyer. The International Energy Agency predicts China`s gas demand will double between 2007 and 2015 and nearly double again from 2015 to 2030. Unlike the U.S., which relies on ethanol, China`s primary alternative fuel is methanol, which is derived from coal, which is very abundant in China. China produces over 10 million tons of domestic alcohol-based automobile clean fuel and is pushing for increased capacity. AJGH has strong government policy and financial support. China`s long term development plan calls for renewable energy to reach 16% of total energy use compared to 1% now and recently adopted fuel-efficiency standards for vehicles that are stricter than the U.S. AJGH has integrated a strategy to becoming a more vertically integrated manufacturer and distributor to increase revenue, margins and profitability. American Jianye Greentech Holdings is currently constructing 2 fuel producing facilities (Tieling and Guangxi) and the company has plans to construct 2 waste-to-fuel facilities (Fujian and Harbin). AJGH recently announced that it has signed a marketing cooperation agreement with Beijing U-fuel New Technology Equipment Co., Ltd, a mobile fuel container manufacturer and marketer and wholly-owned subsidiary of USA-based U-Fuel Group. It is anticipated that American Jianye will expand its distribution network extensively throughout much of China over the next several years through its existing expansion strategy, and the joint marketing with Beijing U-fuel will help accelerate these expansion efforts particularly for retail automotive gas station operators. Haipeng Wang, Chairman and President stated, “As a result of our rapid growth, our investment in new production facilities the third quarter of 2010 has been another record quarter for American Jianye. Our revenue continued increasing sequentially. Revenue for Q3 2010 was $24.8 million, compared to $0 for Q3 2009. Gross profit was $3.3 million for the three months ended September 30, 2010. Net income for the three months ended September 30, 2010 was $2.5 million, or $0.08 per diluted share. Looking ahead, we see our balance sheet and cash flow continuing to improve and we remain extremely confident in projecting over 800% revenue growth in 2010 to $90 million and net income of $9 million, or $0.29 per share.” The company`s near-term goal is to achieve revenue of $150 million with 1-2 years with net profit margins of at least 10%, and over $300 million within 3-5 years. American Jianye Greentech Holdings, Ltd. is poised to become a significant player in the renewable energy industry!
Press Release
Source: American Jianye Greentech Holdings, Ltd.
American Jianye Greentech Holdings Expands Into Alcohol-Based Biodiesel Production With Plan Approval for 200,000 Metric Ton Plant
New Plant Estimated to Generate Incremental Annual Revenue of US$200 million and Net Income of US$16 Million Upon Completion
NEW YORK and HARBIN, China, Feb. 22, 2011 (GLOBE NEWSWIRE) — American Jianye Greentech Holdings, Ltd. (OTCBB: AJGH) , a leading developer, manufacturer and distributor of alcohol-based automobile fuel and civil-use fuel in China, today announced that AJGH has received approval to undertake a new project in alcohol-based biodiesel fuel production. Specifically, AJGH will self-finance the construction of a new biodiesel plant located in the ShiLong Industrial Park in Xiangzhou, Guangxi Province. The Xiangzhou County National Land and Resources Bureau has allocated 10,000 square meters of land in Zone C of the park to American Jianye specifically for the purpose of constructing the new plant.
Mr. Haipeng Wang, Chairman and President, commented, “This approval is another significant acknowledgment and recognition of the technical breakthrough accomplished by our proprietary alcohol-fuel catalyst. With the completion of this new alcohol-based biodiesel plant, estimated for completion by year-end 2011, we will further expand our revenue by venturing into the biodiesel market segment. We anticipate that the new plant will generate additional estimated annual revenue of US$200 million and net income of US$16 million to be realized beginning in 2012.”
American Jianye is and will remain the 100 percent owner of the new plant. The plant will blend ethanol produced from municipal solid waste with diesel fuel imported from Malaysia and/or Indonesia along with AJGH`s proprietary catalyst. The final biodiesel product will contain 40 percent alcohol, much higher than the industry standard 10-20%. AJGH notes that the proprietary catalyst is the most important element of the fuel mix, allowing the higher concentration of alcohol fuel, which results in blended biodiesel fuel that is cleaner and more economical than traditional biodiesel.
AJGH also notes that it has all necessary permitting to move forward with plant construction (including allocation of land, construction, manufacturing and distribution approvals). During the construction phase, AJGH expects to secure progressive approvals related to the construction, and once construction is completed will obtain progressive approvals including a Certificate of Operation, Manufacturing Permit and Distribution Permit.
About American Jianye Greentech Holdings
American Jianye Greentech Holdings, headquartered in Harbin, China, is a leading developer, manufacturer and distributor of alcohol-based fuel. The company`s alcohol-based fuels burn with higher efficiency and significantly lower toxic waste emissions than unleaded gasoline. The unique combination of catalysts in the fuel enhance fuel octane rating and engine power, inhibit the premature oxidation of the fuel, help remove sediment in the carburetor, and prevent the erosion of the engine cylinder surface.
Additional information about the company is available at: www.americanjianyegroup.com .
For additional information please call 800.290.8935 or visit www.market-pulse.com .
This press release contains certain “forward-looking statements” relating to the business of the Company. These forward looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company`s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company`s periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.
Market Pulse All Rights Reserved.
Copyright 2011
American Jianye Greentech Holdings, Inc. (OTCBB: AJGH) Press Release
Dear subscriber,
Welcome to Market Pulse`s online newsletter. Market Pulse is a small-cap investor`s first stop Web page. Each month, our user-friendly Web site profiles new and emerging companies that have excellent potential. We also feature stock picks , quotes, charts, news headlines and other valuable information that is easily accessed. We recommend that anyone investing perform his or her own due diligence.
Market Pulse has issued its current profile for American Jianye Greentech Holdings, Ltd. (OTCBB: AJGH) to the investment community! Stay Tuned For Frequent Updates at www.market-pulse.com .
Featured Company
American Jianye Greentech Holdings, Ltd. (OTCBB: AJGH) is a rapidly growing developer, manufacturer and distributor of alcohol-based and renewable clean fuel products in China. The company`s alcohol-based fuels are comparable to unleaded gasoline with octane ratings ranging from #90 to #108, but burn with higher efficiency and significantly lower toxic waste emissions than unleaded gasoline. The unique combination of catalysts in the fuel enhance fuel octane rating and engine power, inhibit the premature oxidation of the fuel, help remove sediment in the carburetor, and prevent the erosion of the engine cylinder surface. American Jianye has over $15M invested in R&D to date. AJGH has 7 domestic and 2 international patents protecting their unique technology creating many proprietary advantages over competing alcohol-based fuels. Due to their unique technology and process, no engine modifications are required to use their fuels. Similarly, there is no need for gas station modification. AJGH`s process allows for the production of Methanol automobile fuel under normal atmospheric conditions and temperatures, as well as at temperatures as low as -30°C (-22°F). Also, AJGH`s production process produces no significant hazardous waste or pollution. Demand is far outstripping supply for alcohol-based and renewable clean fuel. Chinese consumers were forecasted to buy a record 15 million vehicles in 2010, shattering the record 13.5 million in 2009 that made the country the world`s top car buyer. The International Energy Agency predicts China`s gas demand will double between 2007 and 2015 and nearly double again from 2015 to 2030. Unlike the U.S., which relies on ethanol, China`s primary alternative fuel is methanol, which is derived from coal, which is very abundant in China. China produces over 10 million tons of domestic alcohol-based automobile clean fuel and is pushing for increased capacity. AJGH has strong government policy and financial support. China`s long term development plan calls for renewable energy to reach 16% of total energy use compared to 1% now and recently adopted fuel-efficiency standards for vehicles that are stricter than the U.S. AJGH has integrated a strategy to becoming a more vertically integrated manufacturer and distributor to increase revenue, margins and profitability. American Jianye Greentech Holdings is currently constructing 2 fuel producing facilities (Tieling and Guangxi) and the company has plans to construct 2 waste-to-fuel facilities (Fujian and Harbin). AJGH recently announced that it has signed a marketing cooperation agreement with Beijing U-fuel New Technology Equipment Co., Ltd, a mobile fuel container manufacturer and marketer and wholly-owned subsidiary of USA-based U-Fuel Group. It is anticipated that American Jianye will expand its distribution network extensively throughout much of China over the next several years through its existing expansion strategy, and the joint marketing with Beijing U-fuel will help accelerate these expansion efforts particularly for retail automotive gas station operators. Haipeng Wang, Chairman and President stated, “As a result of our rapid growth, our investment in new production facilities the third quarter of 2010 has been another record quarter for American Jianye. Our revenue continued increasing sequentially. Revenue for Q3 2010 was $24.8 million, compared to $0 for Q3 2009. Gross profit was $3.3 million for the three months ended September 30, 2010. Net income for the three months ended September 30, 2010 was $2.5 million, or $0.08 per diluted share. Looking ahead, we see our balance sheet and cash flow continuing to improve and we remain extremely confident in projecting over 800% revenue growth in 2010 to $90 million and net income of $9 million, or $0.29 per share.” The company`s near-term goal is to achieve revenue of $150 million with 1-2 years with net profit margins of at least 10%, and over $300 million within 3-5 years. American Jianye Greentech Holdings, Ltd. is poised to become a significant player in the renewable energy industry!
Press Release
Source: American Jianye Greentech Holdings, Ltd.
American Jianye Greentech Holdings Renews Product Liability Insurance Policy With Ping An Insurance Company for Third Consecutive Year
No Claims Received Under Existing Policy Reinforces Real World Product Safety
NEW YORK and HARBIN, China, Jan. 25, 2011 (GLOBE NEWSWIRE) — American Jianye Greentech Holdings, Ltd. (OTCBB: AJGH) , a leading developer, manufacturer and distributor of alcohol-based automobile fuel and civil-use fuel in China, today announced that it has renewed for the third year its product liability insurance policy with Ping An Insurance Company covering replacement and/or repair of vehicle engines damaged by American Jianye`s renewable fuel. Under the policy, Ping An provides American Jianye with up to RMB 3.0 million (USD $443,000) in insurance per replacement and/or repair of any vehicle found to be damaged by American Jianye`s fuel. The Company notes that no claims have been filed to date against American Jianye that would potentially be covered by this policy. Consequently, today`s policy renewal and the lack of claims is strong real world evidence of the underlying safety of American Jianye`s product.
Mr. Haipeng Wang, Chairman and Chief Executive Officer, commented, “We are confident and proud that since launching our innovative product in 2002, no product liability complaints or claims have been received by either American Jianye or China Ping An Insurance Company. This track record of zero claims is impressive in its own right and should provide the end user customer, our insurance company and our shareholders with additional high confidence in the quality and safety of our product.”
About American Jianye Greentech Holdings
American Jianye Greentech Holdings, headquartered in Harbin, China, is a leading developer, manufacturer and distributor of alcohol-based fuel. The company`s alcohol-based fuels burn with higher efficiency and significantly lower toxic waste emissions than unleaded gasoline. The unique combination of catalysts in the fuel enhance fuel octane rating and engine power, inhibit the premature oxidation of the fuel, help remove sediment in the carburetor, and prevent the erosion of the engine cylinder surface.
Additional information about the company is available at: www.americanjianyegroup.com .
For additional information please call 800.290.8935 or visit www.market-pulse.com .
This press release contains certain “forward-looking statements” relating to the business of the Company. These forward looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company`s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company`s periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.
Market Pulse All Rights Reserved.
Copyright 2011
5
Healthcare Product Breakthrough Profile Breaking Out to the Upside – OTCBB- MZEI
Comments off · Posted by admin in market-pulse
Market-Pulse.com – Current Profile – (Medizone International, Inc. [OTCBB: MZEI])
Welcome to Market Pulse`s online newsletter. Market Pulse is a small-cap investor`s first stop Web page. Each month, our user-friendly Web site profiles new and emerging companies that have excellent potential. We also feature stock picks, quotes, charts, news headlines and other valuable information that is easily accessed. We recommend that anyone investing perform his or her own due diligence.
Market Pulse is pleased to introduce our featured stock, Medizone International, Inc. (OTCBB: MZEI), to the investment community! Medizone International is poised to become a significant player in the healthcare industry! Medizone International has had some excellent press releases out lately! Investors are starting to realize what a breakthrough healthcare product AsepticSure™ is! We believe the shares are undervalued and are close to a technical breakout to the upside! Once the street and investors figure out what this company has we believe the shares will perform very well! We are very excited about the potential this product and Medizone International has! We believe the stock could be poised for a breakout and a nice run! Stay Tuned For Frequent Updates at www.market-pulse.com .
Medizone International, Inc. (OTCBB: MZEI) is a research and development company engaged in developing AsepticSure™ System, a novel ozone-based technology. AsepticSure™ is a portable decontamination and sterilization system for hospitals, government buildings, sports training facilities, schools and other critical infrastructure that might currently require, or need to be prepared for countermeasures capability from contamination by infectious biological agents. A government variant is being developed for bio-terrorism counter measures. Medizone began mockup trials in January 2010 for both public (hospital) and government (bio-terrorism countermeasures) applications. In March 2010, Medizone successful completed the first full round of room scale testing with its AsepticSure™ sterilization system. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis. The AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard (99.9999% bactericidal kill) on all hospital surfaces, hard or soft. Medizone is now able to greatly reduce the time required to achieve 6 log kills on hard surfaces to 30 minutes of exposure. From a commercial viewpoint, the higher the "kill rate" in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Given the outstanding range of bactericidal kill rates Medizone has achieved to date with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand scientific horizons through collaborative arrangements in many diverse and exciting new applications. Biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control, as one of the greatest threats to public health and safety in the industrial world. Hospital Acquired Infections (HAIs) are one of the most common complications of hospital care. Nearly 2 million patients develop HAIs, which contribute to 99,000 deaths each year and $28 billion to $33 billion in health care costs. Demand for an effective product is huge. Once the trial program for the AsepticSure™ hospital sterilization system is concluded, MZEI expects to out-source the manufacturing of the product and partner with large, well established companies that are already fully embedded in their sector of business as suppliers, such as medical device manufacturers or service companies. Medizone believes that a field hardened variant of the AsepticSure™ hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives. Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market!
The Company
Medizone International, Inc. (OTCBB: MZEI) is a research and development company engaged in developing AsepticSure™ System, a novel ozone-based technology. AsepticSure™ is a portable decontamination and sterilization system for hospitals, government buildings, sports training facilities, schools and other critical infrastructure that might currently require, or need to be prepared for countermeasures capability from contamination by infectious biological agents. It is anticipated that AsepticSure™ will be extremely cost effective and adaptable to virtually any situation anywhere and have a global reach. A government variant is being developed for bio-terrorism counter measures.
Hospital Acquired Infections (HAIs) are one of the most common complications of hospital care. Nearly 2 million patients develop HAIs, which contribute to 99,000 deaths each year and $28 billion to $33 billion in health care costs. The most common HAI-causing bacteria is methicillin-resistant Staphylococcus aureus, or MRSA.
Medizone began mockup trials in January 2010 for both public (hospital) and government (bio-terrorism countermeasures) applications. Results obtained during early February 2010 show that every full-scale test run completed in their hospital room mockup facility has resulted in the total elimination of all bacteria present in the room.
In March 2010, Medizone successful completed the first full round of room scale testing with its AsepticSure™ sterilization system. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile , E coli , Pseudomonas aeruginous , MRSA, VRE and Bacillius subtilis . These results have confirmed the laboratory findings reported earlier, but what is of even greater significance are the insights gained into the technical modifications necessary to accommodate the unique requirements of decontaminating within a hospital environment.
The AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard on all hospital surfaces, hard or soft. Medizone is now able to greatly reduce the time required to achieve 6 log kills on hard surfaces to 30 minutes of exposure. With the charge time and destruct time for reuse of the space factored in, that translates to a room turn around time of 80 minutes, a 40 minute saving in total turn around time from their original target of 2 hours. Fabric exposure requires an additional 15 minutes to achieve the same 6 log kill rate, which represents a full turn around for a thorough cleaning of about 95 minutes for all surface materials. This reduction in room turn around time from 120 minutes to 95 minutes for a thorough sterilization will be viewed very favorably by hospitals.
From a commercial viewpoint, the higher the “kill rate” in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.
The Medizone International Research Laboratory is located in Innovation Park at Queen`s University at Kingston, Ontario, Canada. This laboratory is fully equipped to meet bio-safety level 2 laboratory standards and is dedicated exclusively to Medizone research. This facility provides Medizone International a platform for laboratory research which has the potential to expand beyond AsepticSure™. Given the outstanding range of bactericidal kill rates Medizone has achieved to date with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand scientific horizons through collaborative arrangements in many diverse and exciting new applications.
The AsepticSure™ Sterilization System
Beginning in 2008, Medizone`s management repositioned the company to pursue an initiative in the field of hospital sterilization. Following laboratory results with Bacillus subtilis , an internationally recognized surrogate for Anthrax, that produced 7 log reductions (sterilization), Medizone has expanded their research and business plan to include bio-terrorism countermeasures as well as hospital sterilization and critical infrastructure decontamination. Since this technology is not considered a medical treatment or a diagnostic, its development pathway is not subject to a stringent and expensive regulatory review process.
During July 2009, the company filed a patent application for the AsepticSure™ technology in order to establish protection of its commercial rights to this technology internationally. The patent covers disinfection for rooms and their contents within all healthcare facilities, mobile or stationary, and other critical infrastructure such as schools and government buildings. A second patent application has been filed which in combination with its previous patent application for AsepticSure™ filed in 2009, affords the company greatly enhanced protection for both the hospital version of AsepticSure™ and the government variant intended for bio-terrorism countermeasures. meet the unique challenges of hospital acquired infections, Medizone is utilizing an expanded and enhanced design team that is experienced in bringing products from the research stage to full production. Medizone is finalizing the design of a new, fully integrated AsepticSure™ system for hospital beta testing. Medizone will build four highly instrumented prototype units for use in its hospital program, thereby enabling precise performance assessment of all AsepticSure™ systems as concurrent outcome measures, which will form the basis for final production design work, manufacturing and ultimately commercialization later this year. This design will achieve the same results as the current beta prototype while also being a major step forward and very close to what they expect the full production prototype will be.
The Markets
Biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control, as one of the greatest threats to public health and safety in the industrial world.
Post-surgical infections significantly increase the chance of hospital readmission and death and cost as much as $60,000 per patient, according to Duke University Medical Center researchers who conducted the largest study of its kind to date. Patients with surgical site infections due to MRSA were 35 times more likely to be readmitted and seven times more likely to die within 90 days compared to uninfected surgical patients. For the seven hospitals examined the total estimated cost resulting from surgical site infections due to MRSA was more than $19 million. The cost-saving potential for community hospitals is enormous.
The United States Congress and various State Legislatures have taken official notice of the issues associated with Hospital Acquired Infections. Laws are being enacted in a majority of States to require that hospitals report the number of Hospital Acquired Infections. Medicare will no longer reimburse hospitals for treating hospital acquired infections. Demand for an effective product is huge.
Medizone assisted in the formation of the Canadian Foundation for Global Health (CFGH), a not-for-profit foundation based in Ottawa, Canada. Medizone`s Board of Directors have adopted a business philosophy of "creating a corporate paradigm in which the corporation’s profit follows its social contribution." The establishment of this foundation fits into that paradigm not only by being positioned to attract the highest quality professionals possible to their research projects. It is envisioned that as Medizone`s products and treatments become ready for market, the Foundation may play a vital role as a distribution source for developing countries with varying price breaks depending on the country`s needs and the availability of international assistance.
Medizone International introduced Arkady Mandel MD, PhD, D.Sc as a new member to their team of esteemed consultants. Dr. Mandel was elected in 2009 to the Board of Directors of the Canadian Foundation for Global Health. "In joining our research and development team Dr. Mandel will contribute immensely to our understanding of the complex chemistry behind the broad and potent bactericidal interaction of AsepticSure™" commented DR Michael Shannon, Medizone`s Director of Medical Affairs, who continued, "DR Mandel brings to Medizone almost 25 years of experience with ozone and holds over 30 international patents pertaining to ozone related medical applications. His enormous depth of knowledge and expertise in the biochemistry, physiology and immunology associated with ozone medicine will prove invaluable to our Company particularly as we attempt to both expand and fortify our Intellectual Property position internationally".
Once the trial program for the AsepticSure™ hospital sterilization system is concluded, MZEI expects to out-source the manufacturing of the product and partner with large, well established companies that are already fully embedded in their sector of business as suppliers, such as medical device manufacturers or service companies.
Medizone possibly may partner with several such companies, perhaps covering different geographical markets such as North America, Asia, and Europe. The same may prove to be true for the outsourcing of additional manufacturing capacity. By developing relationships with multiple corporate partners, management believes that they will be able to better maintain control over their products and obtain more competitive returns.
Management Team
Edwin G. Marshall – Chairman of the Board and Chief Executive Officer Michael E. Shannon, M.A.,M.Sc.,M.D. – Board Member & Director of Medical Affairs
Richard Garret Solomon – Director and Executive Officer Daniel D. Hoyt – Board Member Steve M. Hanni – Chief Financial Officer
The Future
The company believes that Medizone`s unique ozone generating technologies could play a vital role in addressing what public health officials and surgeons worldwide are beginning to recognize as "the silent epidemic", a reference to MRSA (methicillin-resistant staphylococcus aureus) infection.
Medizone`s management believes that there is an opportunity to build on the company`s experience with ozone technologies and its bio-oxidative qualities in pursuing this initiative. The company has shifted its near term efforts towards one of its founding tenets, namely that under the right conditions, ozone can be extremely effective at sterilizing virtually all biological fluids (blood, serum, and plasma and its fractionates) as well as all biologically contaminated equipment and spaces.
Medizone’s CEO Edwin Marshall added, “Following the impressive results recently announced for MRSA, we immediately began to assess the capability of AsepticSure™ using the same updated technology with the spore forming bacteria C. difficile , which is ubiquitous within hospitals and chronic care centers. Following those results we then worked with Bacillus subtilis, which represents the infamous and highly lethal terrorist agent, Anthrax. In both cases, these two pathogens remain very resistant to standard decontamination procedures and hence, seeing our technology virtually annihilate these two difficult spore formers has lead Medizone to a parallel track of development with its AsepticSure™ technology which we are convinced will open up the possibility for commercialization in both arenas."
Medizone believes that a field hardened variant of the AsepticSure™ hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives. Medizone International, Inc. is poised to become a significant player in the healthcare industry!
Corporate Information
Symbol:
MZEI
Exchange:
OTCBB
Shares I/O:
242.20 million
Est. Float:
177.41 million
52 Week Range:
$0.016 – $0.42
Contact Information
Investor Relations, Market Pulse
Toll Free:
800.290.8935
Email:
info@market-pulse.com
Web Sites:
www.medizoneint.com
Latest News:
MZEI News
Recent Developments:
April 30, 2010 – MoneyTV with Donald Baillargeon, 4/30 Get the Full Story
April 27, 2010 – MRSA Eliminated in Youth Sports Equipment Get the Full Story
April 13, 2010 – Medizone International to Attend Investors Conference Get the Full Story
March 19, 2010 – MEDIZONE INTERNATIONAL INC Financials Get the Full Story
March 16, 2010 – Medizone International Announces Giant Step Forward for AsepticSure(TM) Get the Full Story
March 15, 2010 – MEDIZONE INTERNATIONAL INC Files SEC form 10-K, Annual Report Get the Full Story
March 8, 2010 – AsepticSure(TM) Eliminates All Pathogens Get the Full Story
February 4 , 2010 – AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs Get the Full Story
January 20, 2010 – Medizone International Announces Greatly Enhanced AsepticSure(TM) Patent Protection Get the Full Story
January 5, 2010 – Medizone International Successfully Completes Third Round of AsepticSure(TM) Test Program Get the Full Story
Market Pulse All Rights Reserved.
©2010 Market Pulse
Market Pulse Report
MP`s Featured Company
Market Pulse is pleased to introduce our featured stock, Medizone International, Inc. (OTCBB: MZEI) , to the investment community! Medizone International is poised to become a significant player in the healthcare industry! Medizone International has had some excellent press releases out lately! Investors are starting to realize what a breakthrough healthcare product AsepticSure™ is! We believe the shares are undervalued and are close to a technical breakout to the upside! Once the street and investors figure out what this company has we believe the shares will perform very well! We are very excited about the potential this product and Medizone International has! We believe the stock could be poised for a breakout and a nice run!
In response to the growing need for the decontamination of sports training facilities and locker rooms from the Super Bug Methicillin-Resistant Staphylococcus Aureus , also known as MRSA, Medizone International, Inc., is pleased to announce that it has successfully sterilized both naturally and artificially contaminated sports equipment using its highly versatile AsepticSure™ sterilization system. "The implications of these results are enormous to Medizone as the potential market for AsepticSure™ has at least quadrupled in size," stated Mr. Marshall, Medizone`s CEO. As reported in a recent article entitled "Assessment of Athletic Facility Surfaces for MRSA in the Secondary School Setting" (Journal of Environmental Health, Feb., 2010) the authors stated that, "Methicillin-Resistant Staphylococcus Aureus (MRSA) was once largely a hospital-acquired infection, but increasingly, community-associated MRSA (CA-MRSA) is causing outbreaks among otherwise healthy people in athletic settings. Secondary school athletic trainers, student athletes, and the general student population may be at elevated risk of MRSA infection.". Part of the test program just completed by Medizone involved the evaluation of a hockey goalie`s glove used for three years by a 12-year-old Canadian boy. The inside surface of the glove was found to be heavily contaminated with MRSA along with a number of other less deadly pathogens. Medizone`s Director of Medical Affairs, Dr Michael Shannon stated, "Pads and team sweaters were also tested and very effectively sterilized without damaging the textiles or leather. It is noteworthy that the protocol used in gloves heavily contaminated with numerous real world pathogens needed to be adjusted significantly from the hospital protocol in order to obtain full sterilization, which demonstrates the ability of the AsepticSure™ system to meet the many varied demands in the real world through protocol changes without the need to alter the technology. This new work has lead to the development of a decontamination protocol specifically for this application which yields results consistent with those expected in hospital setting of 6 logs (99.9999%, sterilization standard) of bacterial kill. Thus, we have now demonstrated that the AsepticSure™ system is capable of cost effective hospital sterilization, locker room and sports equipment sterilization and in due course, we expect to assume a meaningful role in the bio-terrorism counter measures arena as well." Get The Profile
MP`s Hot Stock Picks
Stock Pick Meanings
These stock picks are the investment opinions of MP`s editor and reflect MP`s belief regarding the potential price movement over the next one to four weeks of trading of each of the stocks presented. This analysis is done from a technical and fundamental perspective. MP rates them as follows:
Medizone International Inc. (OTCBB: MZEI): Attractive.
Intel Corporation (Nasdaq: INTC): Bearish.
Microsoft Corporation (Nasdaq: MSFT): Bearish.
Apple Inc. (Nasdaq: AAPL): Market Underperform.
In this issue · MP`s Market Commentary · MP`s Hot Stock Picks · Medizone International Inc. (OTCBB: MZEI) : Attractive. · Intel Corporation (Nasdaq: INTC): Bearish. · Microsoft Corporation (Nasdaq: MSFT): Bearish. · Apple Inc. (Nasdaq: AAPL): Market Underperform.
Market Pulse is pleased to announce the launch of its new brand and website. The new brand and website help to reflect the core nature of our business going forward, enhancing exposure for your company and getting your news disseminated to the financial community. Please visit our new site at www.market-pulse.com .
If you are interested in a proposal for an awareness campaign, please contact Market Pulse LLC at 800-290-8935 or vai email at ceo@market-pulse.com .
Market Pulse All Rights Reserved.
©2010 Market Pulse
